Trials / Completed
CompletedNCT00889200
Eszopiclone Treatment & Cortisol Responsivity
Eszopiclone Treatment & Cortisol Response to HPA Axis Tests
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Butler Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to use a sensitive neuroendocrine probe, the Dexamethasone/Corticotropin-Releasing Hormone (DEX/CRH) test, in a sample of healthy adults with insomnia. The primary aim was to assess cortisol reactivity before and after long-term (6 weeks) administration of eszopiclone. It was hypothesized that treatment with eszopiclone would result in a significant reduction in plasma cortisol response to the DEX/CRH test following treatment of insomnia with standard dose of eszopiclone.
Detailed description
see above
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eszopiclone | 6 weeks standard oral therapy |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-12-01
- Completion
- 2009-08-01
- First posted
- 2009-04-28
- Last updated
- 2017-09-08
- Results posted
- 2014-11-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00889200. Inclusion in this directory is not an endorsement.